Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse

Published:January 05, 2012DOI:



      To evaluate the efficacy of thymosin beta 4 (Tβ4) on hyperglycemia and insulin sensitivity in a mouse model of type 2 diabetes mellitus (T2DM).


      KK mice were divided into the following groups: KK control group, with saline treatment; KK Tβ4 group, with daily Tβ4 100 ng/10 g body weight intraperitoneal injection for 12 weeks. Non-diabetic C57BL mice were used as normal control. OGTT, plasma insulin, HbA1c, serum adiponectin, Tβ4, cholesterol, and triglyceride were measured before and after Tβ4 treatment. The phosphorylated AKT and total AKT protein levels of skeletal muscle from all groups were determined.


      After Tβ4 treatment, repeat OGTT showed a significant decrease in glucose profiles in the KK Tβ4 group compared with the KK control group. The KK-Tβ4 group had reduced mean HbA1c and triglyceride levels, and increased adiponectin compared with KK control group. C57BL mice showed normal glucose homeostasis. The phosphorylated AKT levels of skeletal muscle were significantly increased in KK Tβ4 group compared with KK control group after glucose stimulation. C57BL mice showed no changes in phosphorylated AKT levels after Tβ4 treatment.


      4 improved glucose intolerance and ameliorated insulin resistance in KK mouse. Tβ4 may be a potential alternative insulin sensitizer for treatment of T2DM.


      To read this article in full you will need to make a payment


        • Chen G.
        • Lai X.
        • Jiang Q.
        • Chen F.
        • Chen N.
        • Huang H.
        • et al.
        Cardiovascular disease (CVD) risk, insulin resistance and beta-cell function in prehypertension population of China.
        Atherosclerosis. 2011; 217: 279-285
        • Godsland I.F.
        • Lecamwasam K.
        • Johnston D.G.
        A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index.
        Metabolism. 2011; 60: 1428-1442
        • Reddy K.J.
        • Singh M.
        • Bangit J.R.
        • Batsell R.R.
        The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review.
        J Cardiovasc Med (Hagerstown). 2010; 11: 633-647
        • Winterstein A.G.
        Rosiglitazone and the risk of adverse cardiovascular outcomes.
        Clin Pharmacol Ther. 2011; 89: 776-778
        • Crockford D.
        • Turjman N.
        • Alan C.
        • Angel J.
        Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications.
        Ann N Y Acad Sci. 2010; 1194: 179-189
        • Hinkel R.
        • Bock-Marquette I.
        • Hatzopoulos A.K.
        • Kupatt C.
        Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia.
        Ann N Y Acad Sci. 2010; 1194: 105-111
        • Smart N.
        • Risebro C.A.
        • Clark J.E.
        • Ehler E.
        • Miquerol L.
        • Rossdeutsch A.
        • et al.
        Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart.
        Ann N Y Acad Sci. 2010; 1194: 97-104
        • Shrivastava S.
        • Srivastava Olson E.N.
        • DiMaio J.M.
        • Bock-Marquette I.
        Thymosin beta4 and cardiac repair.
        Ann N Y Acad Sci. 2010; 1194: 87-96
        • Tokura Y.
        • Nakayama Y.
        • Fukada S.
        • Nara N.
        • Yamamoto H.
        Matsuda R, and Hara T. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts.
        J Biochem. 2011; 149: 43-48
        • Ye L.
        • Lee K.O.
        • Su L.P.
        • Toh W.C.
        • Haider H.K.
        • Law P.K.
        • et al.
        Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus.
        Diabetologia. 2009; 52: 1925-1934
        • Saghizadeh M.
        • Kramerov A.A.
        • Tajbakhsh J.
        • Aoki A.M.
        • Wang C.
        • Chai N.N.
        • et al.
        Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas.
        Invest Ophthalmol Vis Sci. 2005; 46: 3604-3615
        • Sosne G.
        • Qiu P.
        • Kurpakus-Wheater M.
        • Matthew H.
        Thymosin beta4 and corneal wound healing: visions of the future.
        Ann N Y Acad Sci. 2010; 1194: 190-198
        • Dunn S.P.
        • Heidemann D.G.
        • Chow C.Y.
        • Crockford D.
        • Turjman N.
        • Angel J.
        • et al.
        Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.
        Ann N Y Acad Sci. 2010; 1194: 199-206
        • Iwatsuka H.
        • Shino A.
        • Suzuoki Z.
        General survey of diabetic features of yellow KK mice.
        Endocrinol Jpn. 1970; 17: 23-35
        • Hemmingsen B.
        • Lund S.S.
        • Wettersle, Jnd Vaag A.
        Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.
        Eur J Endocrinol. 2009; 161: 1-9
        • Everett B.M.
        • Cook N.R.
        • Magnone M.C.
        • Bobadilla M.
        • Kim E.
        • Rifai N.
        • et al.
        Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's health study.
        Circulation. 2011; 123: 2811-2818
        • Bitzur R.
        Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need.
        Diabetes Care. 2011; 34: S380-S382
        • Bloomgarden Z.T.
        Diabetes and cardiovascular disease.
        Diabetes Care. 2011; 34: e24-e30
        • Semenkovich C.F.
        Insulin resistance and atherosclerosis.
        J Clin Invest. 2006; 116: 1813-1822
        • Nigro J.
        • Osman N.
        • Dart A.M.
        • Little P.J.
        Insulin resistance and atherosclerosis.
        Endocr Rev. 2006; 27: 242-259
        • Bock-Marquette I.
        • Saxena A.
        • White M.D.
        • Dimaio J.M.
        • Srivastava D.
        Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
        Nature. 2004; 32: 466-472
        • Zhu J.
        • Yong W.
        • Wu X.
        • Yu Y.
        • Lv J.
        • Liu C.
        • et al.
        Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes.
        Biochem Biophys Res Commun. 2008; 369: 471-477
        • Hotamisligil G.S.
        Inflammation and metabolic disorders.
        Nature. 2006; 444: 860-867
        • Maybee N.A.
        • Worrall B.B.
        • Nadler J.L.
        Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice.
        Nat Clin Pract Endocrinol Metab. 2007; 3: 806-807
        • Young J.D.
        • Lawrence A.J.
        • MacLean A.G.
        • Leung B.P.
        • McInnes I.B.
        • Canas B.
        • et al.
        Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids.
        Nat Med. 1999; 5: 1424-1427
        • Sosne G.
        • Qiu P.
        • Christopherson P.L.
        • Wheater M.K.
        Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway.
        Exp Eye Res. 2007; 84: 663-669
        • Farese R.V.
        • Sajan M.P.
        • Standaert M.L.
        Atypical protein kinase C in insulin action and insulin resistance.
        Biochem Soc Trans. 2005; 33: 350-353
        • Chambers M.A.
        • Moylan J.S.
        • Smith J.D.
        • Goodyear L.J.
        Reid MB.Stretch-stimulated glucose uptake in skeletal muscle is mediated by reactive oxygen species and p38 MAP-kinase.
        J Physiol. 2009; 587: 3363-3373
        • DeFronzo R.A.
        • Tripathy D.
        Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.
        Diabetes Care. 2009; 32: S157-S163
        • Mora C.A.
        • Baumann C.A.
        • Paino J.E.
        • Goldstein A.L.
        • Badamchian M.
        Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.
        Int J Immunopharmacol. 1997; 19: 1-8